Related Experiment Video
Updated: Nov 7, 2025
07:09
A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
Published on: February 18, 2022
2.1K
Medical Therapy of Heart Failure with Reduced Ejection Fraction-A Call for Comparative Research
Gad Cotter1,2, Beth A Davison1,2, Alexandre Mebazaa2,3,4
1Momentum Research, Inc., 50101 Governors Drive, Chapel Hill, NC 27517, USA.
Journal of Clinical Medicine
|April 30, 2021
Summary
New therapies for heart failure with reduced ejection fraction (HFREF) expand treatment options. Renin angiotensin blockers and beta blockers remain foundational, while newer agents like Angiotensin Receptor Neprilysin Inhibitors offer further benefits.
Area of Science:
- Cardiology
- Pharmacology
- Internal Medicine
Background:
- Heart failure with reduced ejection fraction (HFREF) treatment has evolved significantly.
- Multiple drug classes are now available, expanding therapeutic options.
Purpose of the Study:
- To review current data on HFREF therapies.
- To provide guidance on the optimal use of available medications.
Main Methods:
- Review of existing clinical trial data and guidelines.
- Analysis of efficacy, safety, and cost-effectiveness of different drug classes.
Main Results:
- Renin angiotensin blockers (RAASbs) and beta blockers (BBs) are cost-effective cornerstones.
- Angiotensin Receptor Neprilysin Inhibitors (ARNis) should replace RAASbs in symptomatic patients.
- Sodium glucose cotransport inhibitors (SGLTis), ivabradine, and vericiguat are options for persistent symptoms.
Conclusions:
- A multi-drug approach is necessary for HFREF management.
- Further comparative studies are needed to guide optimal sequencing and combination therapy.
- Individualized treatment strategies are crucial due to overlapping side effect profiles.
Related Concept Videos
01:30Heart Failure V: Medical Management
68
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
68
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
646
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
646
01:22Heart Failure VI: Adjunct Therapies
71
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
71
01:30Heart Failure IV: Classification and Diagnostic Evaluation
108
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
108
01:22Heart Failure Drugs: β-Blockers
541
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
541
01:30Cardiomyopathy II: Dilated Cardiomyopathy
118
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
118